P53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary

International Journal of Gynecological Pathology

Volumn 30, Issue 5, 2011, Pages 417-424

  Leonhardt, Karoline ^a   Einenkel, Jens ^a   Sohr, Sindy ^a   Engeland, Kurt ^a   Horn, Lars Christian ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

BRCA; Fallopian tube; Ovarian serous borderline tumor; p53; Peritoneal cancer; Serous pelvic cancer; Serous tubal carcinoma

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; KI 67 ANTIGEN; PROTEIN P53;

ADULT; ARTICLE; CANCER SCREENING; CARCINOMA IN SITU; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CYST; OVARY TUMOR; PELVIS CANCER; PERITONEUM CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROPHYLAXIS; SALPINGOOOPHORECTOMY; STAINING; UTERINE TUBE CARCINOMA;

ADULT; CARCINOMA IN SITU; CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PRECANCEROUS CONDITIONS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80051796593     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e318216d447     Document Type: Article

References (29)

1. Crum CP. Intercepting pelvic cancer in the distal fallopian tube: Theories and realities. Mol Oncol 2009;3:165-70.
2. Herrington CS, McCluggage WG. The emerging role of the distal Fallopian tube and p53 in pelvic serous carcinogenesis. J Pathol 2010;220:5-6.
3. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006;30:230-6.
4. Folkins AK, Jarboe EA, Roh MH, et al. Precursors to pelvic serous carcinoma and their clinical implications. Gynecol Oncol 2009;113:391-6.
5. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007; 25:3985-90.
6. Leeper K, Garcia R, Swisher E, et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002;87:52-6.
7. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2006;100:58-64.
8. Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingooophorectomy in BRCA mutation carriers: Role of serial sectioning in the detection of occult malignancy. J Clin Oncol 2005;23:127-32.
9. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007;31:161-9.
10. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007;211:26-35.
11. Folkins AK, Jarboe EA, Saleemuddin A, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008;109:168-73.
12. Lynch HT, Casey MJ, Snyder CL, et al. Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management. Mol Oncol 2009;3:97-137.
13. Carlson JW, Jarboe EA, Kindelberger D, et al. Serous tubal intraepithelial carcinoma: Diagnostic reproducibility and its implications. Int J Gynecol Pathol 2010;29:310-4.
14. Jarboe E, Folkins A, Nucci MR, et al. Serous carcinogenesis in the fallopian tube: A descriptive classification. Int J Gynecol Pathol 2008;27:1-9.
15. Crum CP, Drapkin R, Kindelberger D, et al. Lessons from BRCA: The tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 2007;5:35-44.
16. Naora H. The heterogeneity of epithelial ovarian cancers: Reconciling old and new paradigms. Expert Rev Mol Med 2007;9:1-12.
17. Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy. Gynecol Oncol 2005;98:179-81.
18. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am J Surg Pathol 2010;34:433-43.
19. Kurman RJ, McConnell TG. Precursors of endometrial and ovarian carcinoma. Virchows Arch 2010;456:1-12.
20. Salvador S, Gilks BKM, Huntsman D, et al. Correlation between ovarian serous adenocarcinoma and fallopian tube involvement. J Obstet Gynecol Cancer 2007;24:S69.
21. Lee KR, Tavassoli FA, Prat J, et al. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003:113-202.
22. Carlson JW, Miron A, Jarboe EA, et al. Serous tubal intraepithelial carcinoma: Its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008;26:4160-5.
23. Biscotti CV, Hart WR. Peritoneal serous micropapillomatosis of low malignant potential (serous borderline tumors of the peritoneum). A clinicopathologic study of 17 cases. Am J Surg Pathol 1992;16:467-75.
24. Weir MM, Bell DA, Young RH. Grade 1 peritoneal serous carcinomas: A report of 14 cases and comparison with 7 peritoneal serous psammocarcinomas and 19 peritoneal serous borderline tumors. Am J Surg Pathol 1998;22:849-62.
25. Cass I, Holschneider C, Datta N, et al. BRCA-mutationassociated fallopian tube carcinoma: A distinct clinical phenotype? Obstet Gynecol 2005;106:1327-34.
26. Levanon K, Ng V, Piao HY, et al. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 2010;29:1103-13.
27. Barakat RR, Federici MG, Saigo PE, et al. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer 2000;89:383-90.
28. Hutson R, Ramsdale J, Wells M. p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology 1995;27:367-71.
29. Kerner R, Sabo E, Gershoni-Baruch R, et al. Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: Correlation with histopathology. Gynecol Oncol 2005;99:367-75.